XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

XTalks

MAY 7, 2021

As Novavax awaits emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for its protein-based COVID-19 vaccine NVX-CoV2373, the company shared new data this week on the vaccine’s efficacy against the South African B.1.351 1.351 variant.

Protein 97

Protein Vaccination Vaccine Trials 97

Drug Discovery World

FEBRUARY 19, 2024

At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus.

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

The Pharma Data

AUGUST 15, 2021

Now, researchers reporting in ACS Central Science have immunized mice with nanoparticles that mimic SARS-CoV-2 by displaying multiple copies of the receptor binding domain (RBD) antigen, showing that the vaccine triggers robust antibody and T cell responses. bioRxiv [Preprint]. 2021 Apr 8:2021.04.08.438884.

Protein 52

Protein Vaccination Vaccine Antibody 52

pharmaphorum

MAY 11, 2021

Flagship Pioneering, the VC fund run by Moderna’s co-founder Noubar Afeyan has launched a new biotech Laronde , with an ambitious plan to create a new class of drugs based on Endless RNA. Called eRNA for short, this class of medicines is programmable and can continuously express therapeutic proteins inside the body.

RNA 98

RNA Drugs Protein Immune Response 98

XTalks

AUGUST 14, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fifth-line treatment for adult patients with heavily pretreated multiple myeloma. Results were similar at the higher 0.8

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 59

Research Immune Response Antibody Medicine 59

The Pharma Data

NOVEMBER 22, 2020

FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). PORTO, Portugal & CAMBRIDGE, England & LONDON–( BUSINESS WIRE )– FairJourney Biologics S.A (FJB)

Antibody 52

Antibody Immune Response Engineer Protein 52

The Pharma Data

DECEMBER 16, 2020

Currently in Phase 3 clinical testing in the United Kingdom for the prevention of COVID-19, NVX-CoV2373 is a recombinant protein vaccine adjuvanted with Novavax’ proprietary Matrix-M to enhance the immune response. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19.

Protein 52

Protein Vaccination Vaccine Immune Response 52

XTalks

AUGUST 8, 2022

MiroBio is a private biotech company based in the UK that focuses on developing checkpoint agonist antibodies, which are a new class of therapies that work to restore immune balance in patients with autoimmune and inflammatory diseases. PD-1 is a potent immune inhibitory receptor. MiroBio’s Research Pursuits.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

Advarra

JANUARY 11, 2024

Adoptive T Cell therapies, therapeutic antibodies, and immunomodulatory proteins represent just some of the potentially beneficial treatment strategies for successful mRNA cancer trials. One strategy proposed the use of synthetic mRNA or modified mRNA analogs, which can enhance the stability and protein expression of mRNA.

Vaccination 52

Vaccination Vaccine Protein Antibody 52

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. Food and Drug Administration (FDA). Roche has filed for Emergency Use Authorisation (EUA) from the U.S.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

The Pharma Data

JANUARY 11, 2021

a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Antibody 52

Antibody Licensing Licensing Development 52

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

pharmaphorum

MAY 27, 2021

GlaxoSmithKline’s COVID-19 drive has advanced on two fronts, with the start of phase 3 trials of its Sanofi-partnered vaccine candidate as well as an FDA emergency approval for antibody sotrovimab, developed with Vir Biotech. “Recent scientific evidence shows that antibodies created against the B.1.351

Antibody 53

Antibody Immune Response Vaccination Vaccine 53

Drug Discovery World

SEPTEMBER 25, 2023

The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, and will evaluate the investigational vaccine for safety and its ability to elicit an immune response. “An The vaccine produced robust antibody responses in animal testing.

Vaccination 52

Vaccination Vaccine Trials Immune Response 52

The Pharma Data

APRIL 15, 2022

Food and Drug Administration in the coming days with additional submissions to other regulatory agencies worldwide to follow. Each serum was tested simultaneously for its neutralizing titer against recombinant SARS-CoV-2 (with USA-WA-1/2020 genetic backbone) bearing the wild-type SARS-CoV-2 spike protein and theOmicron spike.

Immune Response 52

Immune Response Vaccination Vaccine Clinical Trials 52

XTalks

JUNE 15, 2022

Last week, Novavax announced that it received positive feedback from the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) regarding the safety and efficacy of its COVID-9 vaccine (NVX-CoV2373). protein that triggers the immune system to generate antibodies against the virus.

Vaccination 59

Vaccination Vaccine Immune Response Protein 59

Drug Discovery World

JANUARY 17, 2024

Previous work showed that Alpha and Delta evolved to overcome human innate immunity by jamming the cellular signalling in the airways that triggered the antiviral immune response. The findings help to explain why SARS-CoV-2 remains so capable of infecting people despite existing immunity from vaccines and prior infection.

Protein 52

Protein Antibody Vaccination Vaccine 52

XTalks

DECEMBER 12, 2023

Human plasma, the clear, liquid portion of blood, is composed of water, electrolytes, nutrients and crucial proteins such as antibodies, clotting factors and albumin. Patients have better quality of life thanks to many Grifols plasma-derived medicines that replace missing or deficient plasma proteins.

Medicine 111

Medicine Recombinant Antibody Protein Antibody 111

Cloudbyz

MARCH 6, 2024

Traditionally, pharmaceutical therapies have primarily consisted of small molecule drugs, commonly known as pills. This shift signifies not just a change in the way drugs are manufactured and administered, but also a fundamental transformation in the approach to treating diseases at their root cause.

Gene 72

Gene Immune Response Manufacturing Gene Therapy 72

XTalks

APRIL 7, 2021

As the COVID-19 pandemic shifts with new case surges largely owing to new variants of SARS-CoV-2, the US Food and Drug Administration (FDA) continues to offer up emergency use authorizations (EUA) for tests for the detection of COVID-19 infection, with the latest being antibody and antigen tests from Symbiotic and Quidel, respectively.

Antibody 102

Antibody Immune Response Radiology Marketing 102

pharmaphorum

JANUARY 26, 2022

Other studies of the CD47-directed antibody in large B cell lymphoma, multiple myeloma and solid tumours are not affected as they don’t include azacitidine as a study drug. The post FDA slaps hold on trials of Gilead’s CD47 drug magrolimab appeared first on.

Trials 40

Trials Drugs Immune Response Antibody 40

pharmaphorum

AUGUST 24, 2020

With the ink barely dry on a deal to develop Dragonfly’s lead cancer immunotherapy, Bristol-Myers Squibb’s business development team has agreed to buy Canadian biotech Forbius and its pipeline of drugs for cancer and fibrotic diseases. BMS seems to be interested mainly in AVID200’s potential in cancer, however, at least initially.

Immune Response 59

Immune Response Antibody Drugs Licensing 59

XTalks

NOVEMBER 30, 2023

In 2022, the US Food and Drug Administration (FDA) granted approval to the medication Sunlenca (lenacapavir) for adults living with multi-drug resistant HIV-1 infection. Developed by Gilead, Sunlenca is the first drug in a novel class known as capsid inhibitors to receive FDA approval for treating HIV-1.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

DECEMBER 29, 2020

As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes. First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19. Regeneron Pharmaceuticals, Inc. futility analysis). The results passed the futility analysis (p<0.3

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

MARCH 8, 2022

The ongoing SARS-CoV-2 pandemic has caused an imminent urge for both antiviral therapeutical drugs and vaccines. In the light of the further risk of pandemics in the future, however, there remains need for direct antiviral drugs and treatments. Camouflage protects virus from immune system.

Immune Response 52

Immune Response RNA Protein Genetics 52

pharmaphorum

SEPTEMBER 25, 2020

Leap Therapeutics will get a swift FDA review for its lead drug DKN-01 for a form of gastric and gastroesophageal junction (G/GEJ) cancer after being awarded fast-track status by the regulator. In animal models, neutralising DKK1 has been shown to activate an innate immune response against malignant cells.

Immune Response 64

Immune Response Trials Drugs Containment 64

XTalks

MAY 1, 2023

Last week, the US Food and Drug Administration (FDA) granted accelerated approval to Biogen’s Qalsody (tofersen) for the treatment of adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This makes Qalsody the first approved treatment to target a genetic cause of ALS.

FDA Approval 89

FDA Approval Gene Genetics Protein 89

pharmaphorum

JULY 20, 2021

The vaccine – now dubbed Vidprevtyn – is based on a recombinant protein antigen developed by Sanofi’s vaccines unit Sanofi Pasteur, and also includes an immune-boosting adjuvant developed by GSK that aims to boost its efficacy. 1.351) variant first identified in South Africa.

Vaccination 98

Vaccination Vaccine Protein Immune Response 98

XTalks

AUGUST 17, 2020

chimeric receptor antigen [CAR] T cell) immune modulators (i.e. protein-based biologics) and vaccine treatments. Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

FEBRUARY 9, 2022

Closely related to this is the fact that global spending on oncology drugs reached $164 billion in 2020, with drug sales growing at a compound annual growth rate of 14.3% While therapeutic cancer vaccines are able to help the body identify particular proteins expressed by cancer cells and then to instigate an immune response.

Vaccination 132

Vaccination Vaccine Clinical Trials Clinical Trials 132

pharmaphorum

SEPTEMBER 2, 2021

Anna Biosciences’ Dr Anthony Rullo discusses the drug development company’s immunotherapy platform. Over the last 30 years, we have seen dramatic improvements in patient outcomes due to the emergence of biologics – particularly monoclonal antibodies – as therapies for a wide variety of diseases and infections.

Antibody 52

Antibody Protein Immune Response Vaccination 52

Delveinsight

JANUARY 21, 2021

Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. The combination appears to work by activation of the tumour-suppressing protein p53, they announced. billion in total for three drugs. Jacob Van Naarden, M.D.,

Research 52

Research Protein Clinical Trials Clinical Trials 52

pharmaphorum

NOVEMBER 25, 2021

A vaccine delivered by subcutaneous injection targeting tau – a protein which forms tangles that are another feature observed in AD brains – is also being studied by drugmaker Johnson & Johnson in partnership with AC Immune in a phase 1 study. .” Its main objective is gauging the safety and tolerability of the vaccine.

Vaccination 94

Vaccination Vaccine Trials Immune Response 94

The Pharma Data

DECEMBER 3, 2020

S-Trimer adjuvanted with GSK’s pandemic adjuvant system induced neutralizing antibody titers (seroconversion) in 100% of participants at the selected 9 µg S-Trimer dose in both adult and elderly groups, with geometric mean titers (GMT) greater than 1:1,800.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52